Cytogen, a Global Leader in Liquid Biopsy Platforms
Cytogen had established in 2010 with the development of our unique CTC based liquid biopsy platform, created as a result of cooperation between biologists and engineers, and with the hope to open up a new path to benefits cancer patients.
Since then, CytoGen developed a unique chip capable of capturing live CTCs and quickly reached the commercialization level, which might apply to cancer diagnosis and treatment. We further automated the entire liquid biopsy platform, including CTC isolation, detection, and analysis so that we collaborated with several leading domestic and global pharmaceutical companies, prestigious research institutes, and top-tier hospitals. Currently, CytoGen is making strides into a global company based on these global collaborations.
We aim to become the world's best biomedical engineering company through innovative technological advances and our extensive global networking. CytoGen continuously moves forward to achieve our dream by fueling with constant advances in R &D and zeal of contributing to the public goods with sound business ethics.
(05854) 8th floor, Unit A, 128, Beobwon-ro, Songpa-gu, Seoul
CTC characterization using proprietary Liquid Biopsy Platform